Esperion Therapeutics (ESPR) Posts Earnings Results, Beats Estimates By $0.36 EPS

Esperion Therapeutics (NASDAQ:ESPR) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.36, Bloomberg Earnings reports. During the same period in the previous year, the business posted ($1.29) EPS.

Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at $74.92 on Tuesday. The company has a market cap of $1,962.73, a PE ratio of -10.91 and a beta of 2.64. Esperion Therapeutics has a 12-month low of $20.39 and a 12-month high of $82.18.

In related news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 32.50% of the stock is owned by company insiders.

A number of research firms recently issued reports on ESPR. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Bank of America raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price target on the stock in a report on Friday, January 5th. Needham & Company LLC raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and raised their price target for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Chardan Capital raised their price target on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, December 6th. Finally, UBS Group set a $88.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 17th. Six analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Esperion Therapeutics currently has an average rating of “Buy” and an average price target of $77.23.

WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/02/20/esperion-therapeutics-espr-posts-earnings-results-beats-estimates-by-0-36-eps.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply